" class="no-js "lang="en-US"> Modus Submits Patent Application for Sevuparin in Kidney Disease
Sunday, October 01, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Modus Therapeutics Submits Patent Application for Sevuparin in Kidney Disease | PTF

January 23 2023

Modus Therapeutics Submits Patent Application for Sevuparin in Kidney Disease

Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that it has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease.

The patent application is based on novel preclinical work that was undertaken in an established kidney disease animal model during an academic collaboration project. A granted patent would provide patent protection until at least 2043.

Sevuparin is a proprietary compound of Modus Therapeutics, currently being evaluated in Phase 1 clinical trials as a potential treatment for sepsis and septic shock, as well as for severe malaria in children.

John Öhd, CEO of Modus Therapeutics, said: “Sevuparin is already in development as a potential new treatment for sepsis and septic shock. In addition, we are actively evaluating new avenues for development and commercialisation of our key asset, as well as continuously developing its patent portfolio in parallel. While the patent application is a tangible result of these efforts, it also demonstrates Modus´ ability to successfully collaborate internationally with leading academic institutions.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On